Novel expression of a unique ITO cell-specific IGF-binding protein in experimental alcoholic liver disease (ALD): In vivo and ex vivo studies

Hepatology ◽  
1995 ◽  
Vol 22 (4) ◽  
pp. A284
Author(s):  
G BLOCK
Blood ◽  
2011 ◽  
Vol 118 (12) ◽  
pp. 3236-3243 ◽  
Author(s):  
HoangDinh Huynh ◽  
Junke Zheng ◽  
Masato Umikawa ◽  
Chaozheng Zhang ◽  
Robert Silvany ◽  
...  

Abstract The role of IGF binding protein 2 (IGFBP2) in cell growth is intriguing and largely undefined. Previously we identified IGFBP2 as an extrinsic factor that supports ex vivo expansion of hematopoietic stem cells (HSCs). Here we showed that IGFBP2-null mice have fewer HSCs than wild-type mice. While IGFBP2 has little cell-autonomous effect on HSC function, we found decreased in vivo repopulation of HSCs in primary and secondary transplanted IGFBP2-null recipients. Importantly, bone marrow stromal cells that are deficient for IGFBP2 have significantly decreased ability to support the expansion of repopulating HSCs. To investigate the mechanism by which IGFBP2 supports HSC activity, we demonstrated that HSCs in IGFBP2-null mice had decreased survival and cycling, down-regulated expression of antiapoptotic factor Bcl-2, and up-regulated expression of cell cycle inhibitors p21, p16, p19, p57, and PTEN. Moreover, we found that the C-terminus, but not the RGD domain, of extrinsic IGFBP2 was essential for support of HSC activity. Defective signaling of the IGF type I receptor did not rescue the decreased repopulation of HSCs in IGFBP2-null recipients, suggesting that the environmental effect of IGFBP2 on HSCs is independent of IGF-IR mediated signaling. Therefore, as an environmental factor, IGFBP2 supports the survival and cycling of HSCs.


2002 ◽  
Vol 172 (3) ◽  
pp. 467-476 ◽  
Author(s):  
P Grellier ◽  
D Berrebi ◽  
M Peuchmaur ◽  
S Babajko

With a view to investigating the implication of IGF-binding protein-6 (IGFBP-6) in the growth of neuroblastomas, nude mice were injected with IGFBP-6-expressing or control IGR-N-91 human neuroblastoma cells and the resulting xenografts examined. Expression of IGFBP-3, IGFBP-4 and type 1 and type 2 IGF receptor messengers was similar in control tumours and equal-sized IGFBP-6-expressing tumours that had developed. IGF-II was more strongly expressed in control tumours, and IGFBP-6-expressing tumours contained less IGFBP-2 than controls. In both populations, there was a significant positive correlation between IGF-II and IGFBP-2 expression. In small IGFBP-6-expressing xenografts where tumour development had apparently been arrested, haematoxylin--eosin and TUNEL staining revealed numerous apoptotic cells. In situ hybridization indicated homogeneous distribution of the IGFBP-6 signal in test tumours. In cell culture, IGFBP-6-expressing cells expressed similar amounts of IGFBP-2, IGF-II and N-myc mRNAs as control cells; but media conditioned by IGFBP-6-expressing cells contained less intact IGFBP-2 protein, with no increase in its proteolytic fragment. In media treated with plasminogen, in which IGFBP-2 was proteolysed, IGFBP-6 was increased. With its especially strong affinity for IGF-II and its resistance to proteolysis, IGFBP-6 would act by sequestering IGF-II, hence inhibiting its mitogenic and anti-apoptotic effects. In excess, IGFBP-6 would displace IGF-II from IGFBP-2 whose potentiation of IGF-II action would cease and whose susceptibility to degradation would be increased. This study therefore shows that IGFBP-6 plays a role in neuroblastoma cell growth in vivo and in vitro and that stable overexpression of IGFBP-6 leads to alteration of the initial balance between the IGFBPs.


2001 ◽  
Vol 26 (3) ◽  
pp. 229-239 ◽  
Author(s):  
H Song ◽  
JH Shand ◽  
J Beattie ◽  
DJ Flint ◽  
GJ Allan

The IGF-binding protein (IGFBP)-5 protein contains consensus heparin binding motifs in both its carboxy (C)-terminal and central domains, although only the C-terminal site has previously been shown to be functional. We have made two chimeric IGFBP proteins by switching domains between rat IGFBP-5 and -2, named BP552 and BP522 to reflect the domains present, and a truncated rat IGFBP-5 mutant (1-168), named BP550. The ability of these proteins and wild-type (wt) IGFBPs-5 and -2 to bind to either IGFs or heparin was determined using biosensor real-time analysis and heparin ligand blotting respectively. We report that the chimeric molecules have IGF binding affinities comparable to those of the native IGFBPs from which they were derived and, as expected, the binding of BP550 to IGFs was greatly compromised. More surprising was the finding that the ability of BP552 and BP550 to bind to heparin was equivalent to that of wtIGFBP-5, whereas wtIGFBP-2 and BP522 failed to bind. These results demonstrate that the active heparin binding site in BP552 and BP550 is contained within the central domain of IGFBP-5, and that this site is active only in the absence of the C-terminal domain. We subsequently mutated two basic amino acids (R136A:R137A) in the central consensus binding sites between residues 132-140. This resulted in the loss of heparin binding for BP550, confirming the importance of these two basic amino acids in the central domain heparin binding activity. In light of these findings, we suggest that C-terminally truncated fragments of IGFBP-5 generated in vivo by proteolysis could retain heparin/extracellular matrix binding properties.


2001 ◽  
Vol 169 (1) ◽  
pp. 111-122 ◽  
Author(s):  
S Ramos ◽  
L Goya ◽  
C Alvarez ◽  
MA Martin ◽  
AM Pascual-Leone

The effects of different doses of thyroxine (T(4)) delivered by injection or s.c. pellet implantation on alterations of the IGF/IGF binding protein (IGFBP) system were studied in neonatal and adult thyroidectomized (Tx) rats. Body weight, blood glucose, plasma insulin, TSH and GH and pituitary GH content, as well as serum IGF-I, IGF-II, IGFBP-1, -2 and -3 and their liver mRNA expression were assayed. Pellet implantation with the smaller dose of T(4) (1.5 microg/100 g body weight (b.w.) per day) in Tx neonatal rats decreased serum IGF-I, -II and the 30 kDa complex of IGFBPs (IGFBP-1 and -2), and increased serum IGFBP-3. Only the larger dose of T(4) (3 microg/100 g b.w. per day) recovered liver mRNA expression of IGF-I and ensured euthyroid status as shown by the normalized levels of plasma TSH. The rapid increase of body weight and serum GH after T(4) administration indicated a high sensitivity to T(4) during the neonatal period. Serum and liver mRNA expression of IGFs and plasma insulin and GH recovered in adult Tx rats after pellet implantation of 1.75 microg/100 g b.w. per day throughout 10 days. The continuous replacement of T(4) by pellet seems to be the most suitable method for thyroid rehabilitation. A very good correlation was found between insulin and IGF-II in Tx neonates treated with T(4) but not between insulin and IGF-I in Tx adults. IGFBP-2 seems to be up-regulated by T(4) deprivation in neonatal and adult rats. Finally, a good correlation as well as a partial correlation were found between IGFs and thyroid hormones in both neonatal and adult Tx populations, suggesting a direct effect in vivo of T(4) on the hepatic secretion of IGFs, as previously suggested in vitro.


2010 ◽  
Vol 17 (2) ◽  
pp. 293-302 ◽  
Author(s):  
Vladislava Paharkova-Vatchkova ◽  
Kuk-Wha Lee

Tumor suppression by IGF-binding protein 3 (IGFBP3) may occur in an IGF-independent manner, in addition to its role as a regulator of IGF bioavailability. After secretion, IGFBP3 is internalized, rapidly localized to the nucleus, and is later detected in the cytoplasm. We identified a putative nuclear export sequence (NES) in IGFBP3 between amino acids 217 and 228, analogous to the leucine-rich NES sequence of p53 and HIV Rev. Mutation of the NES prevents nucleocytoplasmic shuttling of IGFBP3 and blocks its ability to induce apoptosis. Targeting of IGFBP3 to the mitochondria and endoplasmic reticulum (ER) was confirmed by co-localization with organelle markers using fluorescence confocal microscopy and subcellular fractionation. Mitochondrial targeting was also demonstrated in vivo in IGFBP3-treated prostate cancer xenografts. These results show that IGFBP3 shuttles from the nucleus to the mitochondria and ER, and that nuclear export is essential for its effects on prostate cancer apoptosis.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 323-323
Author(s):  
Matthew Christopher ◽  
Daniel C. Link

Abstract There is considerable evidence showing that osteoblast lineage cells play a key role in regulating hematopoiesis. Less clear is the contribution of hematopoietic cells to osteoblast maintenance. We and others previously showed that treatment with granulocyte-colony stimulating factor (G-CSF) results in a striking loss of osteoblast number and function. Bone marrow transplantation experiments demonstrated that G-CSF does not directly suppress osteoblast function but acts through a transplantable hematopoietic intermediary. Earlier work from our lab suggested that mature neutrophils and B- and T-lymphocytes are dispensable for G-CSF-induced osteoblast loss. We therefore hypothesized that bone marrow monocytes play a role in regulating osteoblasts both during G-CSF treatment and at steady state. To begin to test this hypothesis, primary murine bone marrow stromal cultures—consisting of both adherent macrophages and mesenchymal-lineage stromal cells—were established and cultured three weeks in osteogenic media. Removal of macrophages from these cultures resulted in a striking reduction in osteoblast differentiation, as evidenced by reduced alkaline phosphatase and sharply reduced expression of osteocalcin (92% reduction, p<.0001, n=6), a mature osteoblast marker. To investigate whether bone marrow monocytes play a role in supporting osteoblasts in vivo, we made use of transgenic mice expressing an inducible suicide gene in the monocyte compartment under control of the c-fms promoter. Induction of the suicide gene by administration of an exogenous ligand resulted in efficient deletion of monocytes and macrophages from the bone marrow and peripheral blood. Histomorphometry of long bones showed a striking decrease in osteoblast number in monocyte-ablated mice compared to controls, and osteocalcin mRNA decreased to nearly undetectable levels (n=7 each group). The loss of osteoblasts after monocyte ablation does not result from bystander killing, as other boneassociated cells such as osteoclasts and osteoprogenitors are not decreased. Monocyte ablation and osteoblast loss were associated with a 15-fold mobilization of hematopoietic progenitors (n=5 each group), comparable to levels attained after G-CSF treatment. Taken together, these in vitro and in vivo findings suggest that monocytes provide factors necessary for osteoblast survival or development and raise the possibility that G-CSF administration modulates these factors. As a first step toward identifying these factors, expression profiling of monocytes harvested from the bone marrow of untreated or G-CSF treated mice was performed. These data show that insulin-like growth factor 1 (IGF1) is produced at high levels in resting bone marrow monocytes and is downregulated more than 2.5-fold by G-CSF. Moreover, expression of IGF binding protein 6 (IGFBP6), an IGF binding-protein family member that negatively regulates IGF signaling, is upregulated more than 6-fold in monocytes by G-CSF. Quantitative real time PCR confirmed that IGF- 1 mRNA is reduced >11-fold in bone marrow from monocyte-ablated transgenic mice (p<.05, n=2–3 each group) and >7-fold in wild type mice treated with G-CSF (p<.05, n=3 each group). In addition, IGFBP6 expression was increased ~100-fold in bone marrow during G-CSF treatment. Fractionation of hematopoietic cell populations confirmed that IGFBP6 mRNA and protein is induced in monocyte and granulocyte populations in the bone marrow during G-CSF treatment. Collectively, these data support a model in which monocytes provide signals required for osteoblast maintenance in adult bone marrow. IGF1 signaling is known to play a vital role in osteoblast development and maintenance. Thus, these data also suggest that G-CSF may modulate osteoblast number and function (and secondarily induce hematopoietic stem cell mobilization) through alteration of IGF1 and IGFBP6 expression by monocytes. Studies are underway to directly assess the affect of IGFBP6 on osteoblast survival and differentiation.


Sign in / Sign up

Export Citation Format

Share Document